These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 23177090

  • 1. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
    Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, Gennatas K, Gloor B, Lugli A.
    Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
    [Abstract] [Full Text] [Related]

  • 2. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A, Vlajnic T, Giger O, Karamitopoulou E, Patsouris ES, Peros G, Terracciano LM, Zlobec I.
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [Abstract] [Full Text] [Related]

  • 3. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
    O'Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, Driman DK, Kirsch R, Serra S, Scudamore CH, Renouf DJ, Schaeffer DF.
    Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
    [Abstract] [Full Text] [Related]

  • 4. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [Abstract] [Full Text] [Related]

  • 5. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
    Karamitopoulou E, Wartenberg M, Zlobec I, Cibin S, Worni M, Gloor B, Lugli A.
    Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
    Lenz J, Karasek P, Jarkovsky J, Muckova K, Dite P, Kala Z, Veselska R, Hermanova M.
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
    [Abstract] [Full Text] [Related]

  • 7. Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer.
    Masugi Y, Yamazaki K, Hibi T, Aiura K, Kitagawa Y, Sakamoto M.
    Hum Pathol; 2010 Aug; 41(8):1061-8. PubMed ID: 20413143
    [Abstract] [Full Text] [Related]

  • 8. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
    Rochefort MM, Ankeny JS, Kadera BE, Donald GW, Isacoff W, Wainberg ZA, Hines OJ, Donahue TR, Reber HA, Tomlinson JS.
    Ann Surg Oncol; 2013 Dec; 20(13):4322-9. PubMed ID: 23943022
    [Abstract] [Full Text] [Related]

  • 9. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.
    An W, Ben QW, Chen HT, Zheng JM, Huang L, Li GX, Li ZS.
    Ann Surg Oncol; 2012 Nov; 19(12):3971-8. PubMed ID: 22622471
    [Abstract] [Full Text] [Related]

  • 10. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
    Kohler I, Bronsert P, Timme S, Werner M, Brabletz T, Hopt UT, Schilling O, Bausch D, Keck T, Wellner UF.
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
    [Abstract] [Full Text] [Related]

  • 11. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
    Robinson SM, Rahman A, Haugk B, French JJ, Manas DM, Jaques BC, Charnley RM, White SA.
    Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
    [Abstract] [Full Text] [Related]

  • 12. Tumour budding at invasive margins and outcome in colorectal cancer.
    Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui N, Nakamura T, Watanabe M.
    Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
    [Abstract] [Full Text] [Related]

  • 13. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P, de Figueiredo RS, Leaver H, Ogston S, Kulli C, Polignano FM, Tait IS.
    JOP; 2012 Mar 10; 13(2):199-204. PubMed ID: 22406601
    [Abstract] [Full Text] [Related]

  • 14. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
    Stotz M, Eisner F, Szkandera J, Absenger G, Kornprat P, Lackner C, Samonigg H, Gerger A, Pichler M.
    J Clin Pathol; 2013 Sep 10; 66(9):753-7. PubMed ID: 23750038
    [Abstract] [Full Text] [Related]

  • 15. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
    Wartenberg M, Zlobec I, Perren A, Koelzer VH, Gloor B, Lugli A, Karamitopoulou E.
    Oncotarget; 2015 Feb 28; 6(6):4190-201. PubMed ID: 25669968
    [Abstract] [Full Text] [Related]

  • 16. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, Bassi C, Pederzoli P, Falconi M.
    Surgery; 2012 Sep 28; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.